|

CUE-101 Clinical Trials

2 actively recruiting trials across 2 locations

▲ +1 trial since May 2026

Pipeline

Phase 2: 2

Top Sponsors

  • Yale University1
  • Washington University School of Medicine1

Indications

  • Cancer2
  • HPV Positive Oropharyngeal Squamous Cell Carcinoma1
  • New Diagnosis Tumor1
  • Oropharyngeal Squamous Cell Carcinoma1
  • Locally Advanced1

New Haven, Connecticut1 trial

CUE-101with Pembrolizumab for Locally Advanced HPV+HNSCCs

Yale University

Phase 2

St Louis, Missouri1 trial

Three Schedules of CUE-101 Administered Before Surgery or Definitive Chemoradiation Therapy in HLA-A*0201 Positive Patients With Locally Advanced, HPV16-Positive Oropharyngeal Squamous-Cell Carcinoma

Washington University School of Medicine

Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.